| Dr Robert W Nash, MD | |
|
1750 112th Ave Ne, Suite D050, Bellevue, WA 98004-3752 | |
| (206) 215-3850 | |
| (206) 215-3870 |
| Full Name | Dr Robert W Nash |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 36 Years |
| Location | 1750 112th Ave Ne, Bellevue, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649279456 | NPI | - | NPPES |
| 1015396 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | MD00033892 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pacific Northwest Retina Pllc | 8820494073 | 17 |
News Archive
Single-cell sequencing technologies are filling in fine details in the catalog of life. Researchers at the University of Connecticut Health Center and The Jackson Laboratory have identified 40 subtypes of retinal ganglion cells along with the genetic markers and transcription factors that differentiate them.
A new study suggests young people with a serious genetic blood disorder are not getting the right help at school, especially pupils who miss lessons due to sickness.
Stratatech Corp., a regenerative medicine company focused on the commercialization of cell-based, tissue-engineered skin substitute products, today announced that it has closed a $3.0-million round of funding comprised of convertible notes. The funding was secured from current investors in the company. The proceeds will be used to advance the clinical trial of the company's StrataGraft® living human skin substitute tissue. The company expects to begin Phase IIb of the trial during the second half of 2010.
Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on manipulating the renin angiotensin system (RAS) that both prevents and reverses some characteristics of diabetic retinopathy in a mouse model.
Oxford Immunotec, Inc. announces that a new and specific Current Procedural Terminology (CPT®) code has been established by the American Medical Association for use with the T-SPOT®.TB test. The new Category I code, 86481, is described as "Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension." This new code will be effective as of January 1, 2011.
› Verified 4 days ago
| Entity Name | Proliance Surgeons Inc Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023170313 PECOS PAC ID: 8527972900 Enrollment ID: O20031119000128 |
News Archive
Single-cell sequencing technologies are filling in fine details in the catalog of life. Researchers at the University of Connecticut Health Center and The Jackson Laboratory have identified 40 subtypes of retinal ganglion cells along with the genetic markers and transcription factors that differentiate them.
A new study suggests young people with a serious genetic blood disorder are not getting the right help at school, especially pupils who miss lessons due to sickness.
Stratatech Corp., a regenerative medicine company focused on the commercialization of cell-based, tissue-engineered skin substitute products, today announced that it has closed a $3.0-million round of funding comprised of convertible notes. The funding was secured from current investors in the company. The proceeds will be used to advance the clinical trial of the company's StrataGraft® living human skin substitute tissue. The company expects to begin Phase IIb of the trial during the second half of 2010.
Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on manipulating the renin angiotensin system (RAS) that both prevents and reverses some characteristics of diabetic retinopathy in a mouse model.
Oxford Immunotec, Inc. announces that a new and specific Current Procedural Terminology (CPT®) code has been established by the American Medical Association for use with the T-SPOT®.TB test. The new Category I code, 86481, is described as "Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension." This new code will be effective as of January 1, 2011.
› Verified 4 days ago
| Entity Name | Pacific Northwest Retina Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558940387 PECOS PAC ID: 8820494073 Enrollment ID: O20210930001457 |
News Archive
Single-cell sequencing technologies are filling in fine details in the catalog of life. Researchers at the University of Connecticut Health Center and The Jackson Laboratory have identified 40 subtypes of retinal ganglion cells along with the genetic markers and transcription factors that differentiate them.
A new study suggests young people with a serious genetic blood disorder are not getting the right help at school, especially pupils who miss lessons due to sickness.
Stratatech Corp., a regenerative medicine company focused on the commercialization of cell-based, tissue-engineered skin substitute products, today announced that it has closed a $3.0-million round of funding comprised of convertible notes. The funding was secured from current investors in the company. The proceeds will be used to advance the clinical trial of the company's StrataGraft® living human skin substitute tissue. The company expects to begin Phase IIb of the trial during the second half of 2010.
Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on manipulating the renin angiotensin system (RAS) that both prevents and reverses some characteristics of diabetic retinopathy in a mouse model.
Oxford Immunotec, Inc. announces that a new and specific Current Procedural Terminology (CPT®) code has been established by the American Medical Association for use with the T-SPOT®.TB test. The new Category I code, 86481, is described as "Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension." This new code will be effective as of January 1, 2011.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert W Nash, MD 22232 17th Ave Se Ste 308, Bothell, WA 98021-7425 Ph: (206) 215-3850 | Dr Robert W Nash, MD 1750 112th Ave Ne, Suite D050, Bellevue, WA 98004-3752 Ph: (206) 215-3850 |
News Archive
Single-cell sequencing technologies are filling in fine details in the catalog of life. Researchers at the University of Connecticut Health Center and The Jackson Laboratory have identified 40 subtypes of retinal ganglion cells along with the genetic markers and transcription factors that differentiate them.
A new study suggests young people with a serious genetic blood disorder are not getting the right help at school, especially pupils who miss lessons due to sickness.
Stratatech Corp., a regenerative medicine company focused on the commercialization of cell-based, tissue-engineered skin substitute products, today announced that it has closed a $3.0-million round of funding comprised of convertible notes. The funding was secured from current investors in the company. The proceeds will be used to advance the clinical trial of the company's StrataGraft® living human skin substitute tissue. The company expects to begin Phase IIb of the trial during the second half of 2010.
Pathologic changes of the retina caused by diabetes is the leading cause of blindness in working adults. Diabetic retinopathy has no known cure, treatment options are inadequate, and prevention strategies offer limited protection. In the first of its kind, a report in The American Journal of Pathology describes a potential new intraocular treatment based on manipulating the renin angiotensin system (RAS) that both prevents and reverses some characteristics of diabetic retinopathy in a mouse model.
Oxford Immunotec, Inc. announces that a new and specific Current Procedural Terminology (CPT®) code has been established by the American Medical Association for use with the T-SPOT®.TB test. The new Category I code, 86481, is described as "Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension." This new code will be effective as of January 1, 2011.
› Verified 4 days ago
Kristin J Tarbet, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1810 116th Ave Ne Ste D1, Bellevue, WA 98004 Phone: 425-455-2131 Fax: 425-455-2335 | |
Dr. Ruth W Miller, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1300 116th Ave Ne, Bellevue, WA 98004 Phone: 425-454-7912 Fax: 425-454-7034 | |
Michael E Lee, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 11511 Ne 10th St, Bellevue, WA 98004 Phone: 425-502-3000 | |
Dr. Michael Rizen, M.D., PH.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1300 116th Ave Ne, Bellevue, WA 98004 Phone: 425-454-7912 Fax: 425-452-8720 | |
Charles D Birnbach, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1750 112th Ave Ne, Suite D050, Bellevue, WA 98004 Phone: 206-215-3850 Fax: 206-215-3870 | |
Dr. James Leonard Stroh, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1300 116th Ave Ne, Bellevue, WA 98004 Phone: 425-454-7912 Fax: 425-454-7034 | |
William Winston Waugh Sr., DO Ophthalmology Medicare: Medicare Enrolled Practice Location: 12301 Ne 10th Pl Ste 200, Bellevue, WA 98005 Phone: 425-450-2020 Fax: 425-688-0620 |